Karen Ruth Reed

Karen Ruth Reed

Auto-generated profile, based on publicly available information

Karen Ruth Reed

Cardiff School of Biosciences, Cardiff University, Museum Avenue, Cardiff CF103US, UK

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 June 2004 in Genes & Development
Verified
Journal Article
Open access
PDF file
OSOwen Sansom
Owen Sansom
KRKaren R. Reed
Karen R. Reed
AHAnthony J Hayes
Anthony J Hayes
HIHeather Ireland
Heather Ireland
HBHannah Brinkmann
Hannah Brinkmann
DWDouglas J. Winton
Douglas J. Winton
Although Apc is well characterized as a tumor-suppressor gene in the intestine, the precise mechanism of this suppression remains to be defined. Using a novel inducible Ahcre transgenic line in conjunction with a loxP-flanked Apc allele we, show that loss of Apc acutely activates Wnt signaling through the nuclear accumulation of β-catenin. Coincidentally, it perturbs differentiation, migration, proliferation, and apoptosis, such that Apc-deficient cells maintain a “crypt progenitor-like” phenotype. Critically, for the first time we confirm a series of Wnt target molecules in an in vivo setting and also identify a series of new candidate targets within the same setting.

21 March 2007 in Nature
Verified
Journal Article
Closed access
PDF file
OSOwen Sansom
Owen Sansom
VMValerie S. Meniel
Valerie S. Meniel
VMVanesa Muncan
Vanesa Muncan
TPToby Phesse
Toby Phesse
JWJulie A. Wilkins
Julie A. Wilkins
ACAlan R. Clarke
Alan R. Clarke

1 June 2009 in Gastroenterology
Verified
Journal Article
Closed access
PDF file
ZBZoé D. Burke
Zoé D. Burke
KRKaren R. Reed
Karen R. Reed
TPToby Phesse
Toby Phesse
OSOwen Sansom
Owen Sansom
ACAlan R. Clarke
Alan R. Clarke
DTDavid Tosh
David Tosh

3 August 2015 in The EMBO Journal
Verified
Journal Article
Open access
PDF file
DHDavid J Huels
David J Huels
RRRachel A Ridgway
Rachel A Ridgway
SRSorina Radulescu
Sorina Radulescu
MLMarc Leushacke
Marc Leushacke
ACAndrew D Campbell
Andrew D Campbell
OSOwen Sansom
Owen Sansom
Wnt pathway deregulation is a common characteristic of many cancers. Only colorectal cancer predominantly harbours mutations in APC , whereas other cancer types (hepatocellular carcinoma, solid pseudopapillary tumours of the pancreas) have activating mutations in β‐catenin (CTNNB1) . We have compared the dynamics and the potency of β‐catenin mutations in vivo . Within the murine small intestine (SI), an activating mutation of β‐catenin took much longer to achieve Wnt deregulation and acquire a crypt‐progenitor cell (CPC) phenotype than Apc or Gsk3 loss. Within the colon, a single activating mutation of β‐catenin was unable to drive Wnt deregulation or induce the CPC phenotype. This ability of β‐catenin mutation to differentially transform the SI versus the colon correlated with higher expression of E‐cadherin and a higher number of E‐cadherin:β‐catenin complexes at the membrane. Reduction in E‐cadherin synergised with an activating mutation of β‐catenin resulting in a rapid CPC phenotype within the SI and colon. Thus, there is a threshold of β‐catenin that is required to drive transformation, and E‐cadherin can act as a buffer to sequester mutated β‐catenin.

11 October 2004 in Oncogene
Verified
Journal Article
Closed access
PDF file
KRKaren R Reed
Karen R Reed
OSOwen Sansom
Owen Sansom
AHAnthony J Hayes
Anthony J Hayes
AGAndreas J Gescher
Andreas J Gescher
DWDouglas J Winton
Douglas J Winton
ACAlan R Clarke
Alan R Clarke

1 August 2005 in Journal of Biological Chemistry
Verified
Journal Article
Open access
OSOwen Sansom
Owen Sansom
KRKaren R. Reed
Karen R. Reed
MWMarc van de Wetering
Marc van de Wetering
VMVanesa Muncan
Vanesa Muncan
DWDouglas J. Winton
Douglas J. Winton
ACAlan R. Clarke
Alan R. Clarke
Cyclin D1 is postulated to be a target of the canonical Wnt pathway and critical for intestinal adenoma development. We show here that, unlike cyclin D1 reporter assays, endogenous cyclin D1 levels are not affected following antagonism of the Wnt pathway in vitro, nor is cyclin D1 immediately up-regulated following conditional loss of Apc in vivo. Cyclin D1 levels do, however, increase in a delayed manner in a small subset of cells, suggesting such up-regulation occurs as a secondary event. We also analyzed the immediate consequences of Apc loss in a cyclin D1(-/-) background and failed to find any cyclin D1-dependent phenotypes. However, we did observe elevated cyclin D1 expression in lesions developing 20 days after Apc loss. In these circumstances, all adenomas (but not smaller lesions) showed cyclin D1 up-regulation. Finally in a smaller study, we analyzed whether cyclin D1 deficiency affected adenoma formation 20 days following induced loss of Apc. Unlike AhCre(+) Apc(fl/fl) mice (which all developed adenomas), doubly mutant AhCre(+) Apc(fl/fl) cyclin D1(-/-) mice only developed small lesions. Taken together, this argues that cyclin D1 up-regulation in intestinal neoplasia is important for tumor progression rather than initiation.